Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome
| Autor: | Gloria Michelle Ducasa, Mengyuan Ge, Alla Mitrofanova, Sydney S. Wilbon, Jin Ju Kim, Gabriel Contreras, Judith Molina, Xiaochen Liu, Javier Varona Santos, Antonio Fontanella, Christopher E. Pedigo, Yelena Drexler, Shamroop K. Mallela, Sandra Merscher, Hassan Al-Ali, Alessia Fornoni, Robert G. Nelson |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Sterol O-acyltransferase 030232 urology & nephrology Nephritis Hereditary Mice 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Diabetes mellitus Diabetes Mellitus medicine Albuminuria Animals Humans Diabetic Nephropathies Alport syndrome SOAT1 Kidney biology Podocytes business.industry Cholesterol medicine.disease 030104 developmental biology Endocrinology medicine.anatomical_structure chemistry Nephrology ABCA1 biology.protein lipids (amino acids peptides and proteins) business Kidney disease |
| Zdroj: | Kidney International. 98:1275-1285 |
| ISSN: | 0085-2538 |
| Popis: | Defective cholesterol metabolism primarily linked to reduced ATP-binding cassette transporter A1 (ABCA1) expression is closely associated with the pathogenesis and progression of kidney diseases, including diabetic kidney disease and Alport Syndrome. However, whether the accumulation of free or esterified cholesterol contributes to progression in kidney disease remains unclear. Here, we demonstrate that inhibition of sterol-O-acyltransferase-1 (SOAT1), the enzyme at the endoplasmic reticulum that converts free cholesterol to cholesterol esters, which are then stored in lipid droplets, effectively reduced cholesterol ester and lipid droplet formation in human podocytes. Furthermore, we found that inhibition of SOAT1 in podocytes reduced lipotoxicity-mediated podocyte injury in diabetic kidney disease and Alport Syndrome in association with increased ABCA1 expression and ABCA1-mediated cholesterol efflux. In vivo, Soat1 deficient mice did not develop albuminuria or mesangial expansion at 10-12 months of age. However, Soat1 deficiency/inhibition in experimental models of diabetic kidney disease and Alport Syndrome reduced cholesterol ester content in kidney cortices and protected from disease progression. Thus, targeting SOAT1-mediated cholesterol metabolism may represent a new therapeutic strategy to treat kidney disease in patients with diabetic kidney disease and Alport Syndrome, like that suggested for Alzheimer's disease and cancer treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|